Pharmacogenomic Testing to Guide Antidepressant Use Beneficial in Major Depression
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 22, 2023 -- For patients with major depressive disorder, pharmacogenomics testing to guide antidepressant use yields population health gains and reduces health system costs, according to a study published online Nov. 14 in CMAJ, the journal of the Canadian Medical Association.
Shahzad Ghanbarian, Ph.D., from the University of British Columbia in Vancouver, Canada, and colleagues developed a discrete-time microsimulation model of care pathway for major depressive disorder in British Columbia to examine the effectiveness and cost-effectiveness of pharmacogenomic testing from the public payer's perspective. Incremental costs, life-years, and quality-adjusted life-years (QALYs) were estimated for a representative cohort of patients.
The researchers found that pharmacogenomic testing was predicted to save the British Columbia health system $956 million over 20 years ($4,926 per patient) and bring health gains of 0.064 and 0.381 life-years and QALYs per patient, respectively, if implemented for adult patients with moderate-to-severe major depressive disorder. The savings were mostly as a result of slowing or preventing the transition to refractory depression. Over 20 years, pharmacogenomic-guided care was associated with 37 percent fewer patients with refractory depression. The costs of pharmacogenomics testing would be offset within about two years of implementation as estimated in sensitivity analyses.
"Interventions that might improve remission rates and reduce the number of cases of refractory depression, in particular, are needed to improve the quality of life for patients, and reduce the economic burden of major depressive disorder on already strained health care systems," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Virtual Reality Therapy Can Augment Depression Treatment
MONDAY, May 13, 2024 -- Extended reality-enhanced behavioral activation (XR-BA) may be a feasible, noninferior, and acceptable enhancement to traditional BA for major depressive...
Risk for Depressive Symptoms Increased for Perimenopausal Women
THURSDAY, May 9, 2024 -- Perimenopausal women have an increased risk for depressive symptoms and diagnoses, according to a review published in the July 15 issue of the Journal of...
Majority of U.S. Adults Give Health Care System a 'D' for Handling Mental Health
WEDNESDAY, May 8, 2024 -- Three-quarters of U.S. adults believe mental health issues are identified and treated worse than physical health issues, according to the results of a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.